clinical trial · NCT05712200
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Anthos Therapeutics, Inc.·phase3·recruiting·n = 1,900
Atrial Fibrillation (AF)AbelacimabPlacebo
brief summary
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
started
Dec 27, 2022
primary completion
Aug 31, 2026
completion
Oct 31, 2026
last updated
Mar 31, 2026
official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol